Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
108.29
-0.71 (-0.65%)
Nov 10, 2026, 9:39 AM EST - Market open
Spyre Therapeutics Employees
Spyre Therapeutics had 130 employees as of September 30, 2026. The number of employees increased by 35 or 36.84% compared to the same quarter last year. That makes Spyre Therapeutics the 29,821st largest employer in the world and 3,790th in the United States.
Employees
130
Change (1Y)
35
Growth (1Y)
36.84%
Revenue / Employee
n/a
Profits / Employee
-$1,723,115
Market Cap
10.28B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 130 | 35 | 36.84% |
| Jun 30, 2026 | 125 | 38 | 43.68% |
| Mar 31, 2026 | 112 | 39 | 53.42% |
| Dec 31, 2025 | 102 | 37 | 56.92% |
| Sep 30, 2025 | 95 | 35 | 58.33% |
| Jun 30, 2025 | 87 | 27 | 45.00% |
| Mar 31, 2025 | 73 | 43 | 143.33% |
| Dec 31, 2024 | 65 | 35 | 116.67% |
| Sep 30, 2024 | 60 | 46 | 328.57% |
| Dec 31, 2023 | 30 | -39 | -56.52% |
| Jun 30, 2023 | 14 | -78 | -84.78% |
| Mar 31, 2023 | 61 | -38 | -38.38% |
| Dec 31, 2022 | 69 | -32 | -31.68% |
| Sep 30, 2022 | 69 | -21 | -23.33% |
| Jun 30, 2022 | 92 | 1 | 1.10% |
| Mar 31, 2022 | 99 | 11 | 12.50% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,000 |
| Madrigal Pharmaceuticals | 915 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| TG Therapeutics | 399 |
SYRE News
- 3 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 6 days ago - Spyre Therapeutics price target lowered to $120 from $123 at Wedbush - TheFly
- 6 days ago - Spyre Therapeutics price target raised to $131 from $123 at Stifel - TheFly
- 6 days ago - Spyre Therapeutics reports Q3 EPS (94c), consensus (84c) - TheFly
- 6 days ago - Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 days ago - Spyre Therapeutics Quarterly report: Q3 2026 - Filings
- 7 days ago - Spyre Therapeutics Earnings release: Q3 2026 - Filings
- 21 days ago - Citi ups Spyre target, opens ‘upside 90-day catalyst watch’ - TheFly